Nature Reviews Neurology (2020) https://doi.org/10.1038/s41582-020-0385-8 Published online 08 July 2020
In the originally published version of this article, the description of the study by Sormani et al. (ref. 14) in the third paragraph of the section entitled ‘B cell-depleting therapies’ was incorrect. The description should read:
In 232 patients with multiple sclerosis and suspected or proven COVID-19, the severity of COVID-19 was classified as mild (no or mild pneumonia) in 222 (96%), severe (shortness of breath, respiratory rate ≥30 breaths/min, blood oxygen saturation ≤93%, PaO2:FiO2 < 300 mmHg/%, and an increase in lung infiltrates of >50% within 24–48 h) in 4 (2%) and critical (respiratory failure, septic shock and multiple organ dysfunction or failure) in 6 (3%). Of the 6 patients with critical illness, 1 recovered and 5 died. Of 28 patients receiving a B cell-depleting therapy, 3 (10%) developed a severe or critical disease course14.
This description has been corrected in the HTML and PDF versions of the article.
About this article
Cite this article
Korsukewitz, C., Reddel, S.W., Bar-Or, A. et al. Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature. Nat Rev Neurol (2020). https://doi.org/10.1038/s41582-020-0392-9